- Conditions
- Neuroblastoma, Refractory Neuroblastoma, Relapsed Neuroblastoma, Relapsed Osteosarcoma, Refractory Osteosarcoma
- Interventions
- Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate
- Combination Product
- Lead sponsor
- Emory University
- Other
- Eligibility
- 12 Months and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 156
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Adenocarcinoma
- Interventions
- Zoledronic acid
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Breast Neoplasms
- Interventions
- Zometa, Epirubicin, Docetaxel, Trastuzumab, External beam radiation, Modified radical mastectomy or breast conserving surgery with axillary lymph node dissection
- Drug · Radiation · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2011
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Multiple Myeloma
- Interventions
- Zoledronic Acid
- Drug
- Lead sponsor
- Hoosier Cancer Research Network
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 8
- States / cities
- Elkhart, Indiana • Evansville, Indiana • Indianapolis, Indiana + 3 more
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- denosumab, teriparatide, Zoledronic acid
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 45 Years and older · Female only
- Enrollment
- 76 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Prostate Cancer
- Interventions
- Zometa
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2013
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Osteoporosis
- Interventions
- Raloxifene, Zoledronic acid, Placebo oral pills, Placebo intravenous (i.v.) infusion
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 45 Years to 80 Years · Female only
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Buena Park, California • Washington D.C., District of Columbia + 12 more
- Conditions
- Breast Cancer
- Interventions
- clodronate disodium, demeclocycline hydrochloride, ibandronate sodium, tetracycline hydrochloride, zoledronic acid, laboratory biomarker analysis, adjuvant therapy, computed tomography, dual x-ray absorptiometry
- Drug · Other · Procedure
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Spinal Cord Injury, Acute Spinal Cord Injury, Bone Loss, Osteoporosis
- Interventions
- Zoledronic acid, Placebo
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 2
- States / cities
- Chicago, Illinois
- Conditions
- Pain, Bone Neoplasm, Neoplasm Metastasis
- Interventions
- ibandronate [Bondronat], zoledronic acid
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 3
- States / cities
- Miami, Florida • Macon, Georgia • Houston, Texas
- Conditions
- Sickle Cell Disease
- Interventions
- Placebo, Zoledronic Acid
- Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Bariatric Surgery Candidate, Bone Loss, Bone Resorption
- Interventions
- Zoledronic Acid 5 mg/Bag 100 ml Inj, Placebos
- Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Neuroblastoma
- Interventions
- Bevacizumab, cyclophosphamide, zoledronic acid
- Drug
- Lead sponsor
- New Approaches to Neuroblastoma Therapy Consortium
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2019
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Palo Alto, California • San Francisco, California + 10 more
- Conditions
- Osteoporosis, Post-menopausal
- Interventions
- Teriparatide, Zoledronic Acid
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 55 Years to 89 Years · Female only
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 9
- States / cities
- Lakewood, Colorado • Atlanta, Georgia • Gainesville, Georgia + 6 more
- Conditions
- Bariatric Surgery Candidate
- Interventions
- Zoledronic Acid, Calcium citrate + vitamin D, Vitamin D3
- Drug · Dietary Supplement
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 25 Years to 100 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Osteoporosis
- Interventions
- zoledronic acid
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 45 Years to 79 Years · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • San Diego, California • Denver, Colorado + 15 more
- Conditions
- Solitary Osseous Plasmacytoma
- Interventions
- ixazomib, lenalidomide, dexamethasone, zoledronic acid
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 388
- States / cities
- Anchorage, Alaska • Burbank, California • Clovis, California + 267 more
- Conditions
- Pain, Bone Neoplasm, Neoplasm Metastasis
- Interventions
- ibandronate [Bondronat], zoledronic acid
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Sedona, Arizona • Ocoee, Florida + 22 more
- Conditions
- Post-menopausal Osteoporosis
- Interventions
- Placebo, Zoledronic acid
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 65 Years and older · Female only
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 10
- States / cities
- San Diego, California • Lakewood, Colorado • Gainesville, Georgia + 7 more
- Conditions
- Osteoporosis
- Interventions
- Atorvastatin
- Drug
- Lead sponsor
- Children's Mercy Hospital Kansas City
- Other
- Eligibility
- 6 Years to 25 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Progeria, Hutchinson-Gilford Syndrome
- Interventions
- Lonafarnib, Zoledronic Acid, Pravastatin
- Drug
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- Not listed
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Carcinoma, Non-Small Cell Lung, Carcinoma, Small Cell Lung, Metastases
- Interventions
- zoledronic acid
- Drug
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Bariatric Surgery Candidate, Bone Loss
- Interventions
- Denosumab, Placebo, Zoledronic Acid
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 25 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 2
- States / cities
- San Francisco, California • Boston, Massachusetts
- Conditions
- Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
- Interventions
- Zumsemetinib, Capecitabine, Zoledronic acid, Denosumab
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 3
- States / cities
- Westwood, Kansas • Rochester, Minnesota • St Louis, Missouri